Docetaxel

Country: Нови Зеланд

Језик: Енглески

Извор: Medsafe (Medicines Safety Authority)

Активни састојак:

Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg

Доступно од:

REX Medical Ltd

INN (Међународно име):

Docetaxel trihydrate 25.177 mg (equivalent to anhydrous docetaxel 20mg)

Дозирање:

20 mg/mL

Фармацеутски облик:

Concentrate for infusion

Састав:

Active: Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection

Јединице у пакету:

Vial, glass, Diluent, 1.5 mL

Класа:

Prescription

Тип рецептора:

Prescription

Произведен од:

Cipla Ltd

Терапеутске индикације:

Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.

Резиме производа:

Package - Contents - Shelf Life: Vial, glass, Diluent - 1.5 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 20 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Датум одобрења:

2006-06-23